Our drug-combination screen and previous studies have demonstrated that DU-145 prostate cancer cells are very sensitive to the combination of temozolomide with PARP inhibition, and PARP trapping has been demonstrated in these cells [22, 23]. The gene discussed is PARP1; the disease is prostate carcinoma.